Life Insurance
Consensus Index

AI Consensus Fit Review

National Life Group Indexed Universal Life Insurance With Chronic Illness or Long-Term Care Riders Fit Review

National Life Group is a good fit for a buyer who specifically wants indexed universal life with an optional chronic-illness acceleration rider, with important qualifications.

Research: 2026-09-207 usable platform responsesRead the methodology ↗

Share

Answer Capsule

National Life Group is a good fit for a buyer who specifically wants indexed universal life with an optional chronic-illness acceleration rider, with important qualifications. Two of seven platforms named National Life Group during the ranking stage (google, perplexity), and it finished sixth overall with an average listed rank of 2.5. The strongest reason to consider it is the FlexLife Indexed Universal Life (LSW) with the optional Premium Chronic Care Rider, which company materials describe as dollar-for-dollar death-benefit access up to $3 million with no waiting period. The main limitation is that the rider is optional, costs extra, is unavailable in California and New York, and no public standardized pricing exists [1].

Research Snapshot

FieldFinding
Platform mentions in ranking stage2 of 7 platforms (google, perplexity)
Share of included platform responses28.6%
Average listed rank2.5
Best listed rank2 (perplexity)
Relevant product/model/planFlexLife Indexed Universal Life (LSW) with the optional Premium Chronic Care Rider
Overall use-case fitStrong (1 platform); Good (5 platforms); Uncertain (1 platform) — 7 platforms analyzed
Research date2026-09-20

Why National Life Group Qualified for This Study

Questions This Section Answers

  • Is National Life Group a good choice for Indexed Universal Life Insurance With Chronic Illness or Long-Term Care Riders?
  • How many AI platforms named National Life Group for IUL with chronic illness riders, and at what rank?
  • What product did National Life Group qualify with for this chronic illness rider use case?

National Life Group qualified because it offers a named indexed universal life product paired with a named chronic-illness acceleration rider, which is the exact combination this study screened for. Two of seven platforms named the carrier during ranking discovery — google at rank 3 and perplexity at rank 2 — giving an average listed rank of 2.5 and a best rank of 2. That is a 28.6% share of included platform responses, and the entity finished sixth overall in the final ordering.

The qualifying product is FlexLife Indexed Universal Life, issued by life insurance Company of the Southwest (LSW), with the optional Premium Chronic Care Rider [4]. National Life Group is a trade name; the contractual insurer may be National Life Insurance Company or Life Insurance Company of the Southwest, and each entity is responsible for its own obligations [4].

Platform fit ratings were not unanimous: five platforms rated the fit good, one rated it strong, and one rated it uncertain. That spread is itself a finding — the product is well documented in company materials but thinly covered by independent comparisons.

The Product, Model, Plan, or Service Most Relevant to Indexed Universal Life Insurance With Chronic Illness or Long-Term Care Riders

Questions This Section Answers

  • Which National Life Group plan should a buyer choose if they need chronic illness living benefits inside an IUL?
  • How much of the death benefit can the Premium Chronic Care Rider accelerate, and what monthly payout percentages are available?
  • Is the Premium Chronic Care Rider the same as long-term care insurance?

The relevant offering is FlexLife Indexed Universal Life issued by Life Insurance Company of the Southwest, with the optional Premium Chronic Care Rider available at an additional charge [7]. FlexLife is described as permanent indexed universal life with potential tax-deferred cash-value accumulation, where indexed interest is not direct equity ownership and may be limited by caps or other crediting parameters [7].

Company consumer material states that a qualifying chronic-illness diagnosis may permit access to the full death benefit during the insured's lifetime, up to $3 million, with no waiting period. The rider payout is generally selected at issue at 2% or 4% monthly, subject to the IRS per-diem limit and policy terms [7]. Multiple platforms describe the rider as dollar-for-dollar rather than actuarially discounted, in contrast to the no-cost standard chronic illness accelerated benefit rider [12].

This is not long-term care insurance. FlexLife with a chronic care rider is a life insurance policy with an accelerated death benefit rider and does not qualify for the NY State Long-Term Care Partnership program [15]. One public rider guide says proceeds may be used for non-medical expenses and home modifications, while Massachusetts treatment is restricted to qualified long-term-care services [12].

What the AI Platforms Agreed About

Questions This Section Answers

  • What do AI platforms agree on about National Life Group's FlexLife IUL chronic care rider?
  • Do the platforms agree that National Life Group's chronic illness rider has no waiting period and pays dollar-for-dollar?

Agreement was strong on the core product mechanics. Platforms consistently described the Premium Chronic Care Rider as an optional, separately charged rider that accelerates the death benefit on a non-discounted basis, with no waiting period, up to a stated $3 million maximum, at 2% or 4% monthly payouts subject to IRS per-diem limits [16].

Platforms also agreed on the state restriction: the Premium Chronic Care Rider is not available in California or New York [22]. They agreed the payout percentage is elected at issue and can be reduced but not increased afterward [16].

On financial strength, platforms cited an AM Best A+ (Superior) financial-strength rating with a stable outlook for National Life Insurance Company and Life Insurance Company of the Southwest, affirmed in 2026 [26]. Ratings are opinions, can change, and do not guarantee policy performance or claims payment [27].

Platforms also agreed that monthly policy fees, expense charges, cost-of-insurance charges, and rider charges continue regardless of indexed crediting, including periods when the policy credits 0% [31].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

  • Why did one AI platform rate National Life Group's FlexLife IUL chronic care rider as uncertain rather than good?
  • Do the platforms disagree about whether National Life Group's living benefits are free or cost extra?

The most significant disagreement is about documentation and verifiability. Kimi rated the fit uncertain, stating that the exact product name could not be verified against National Life Group's public website in its search results, that it could not determine whether "Chronic Care" is a chronic illness rider, an LTC rider, or a hybrid structure, and that no independent review or comparison data was found for this specific rider [32]. Kimi's conclusion was that buyers must obtain complete policy documentation and illustrations from an appointed agent to assess suitability.

Google rated the fit strong, calling the Premium Chronic Care Rider "class-leading" for non-discounted dollar-for-dollar payouts with no waiting period, while also noting that independent analysts describe FlexLife cash accumulation as average compared with dedicated cash-growth carriers [33].

Perplexity flagged a conflict in the public record: sources disagree on whether the broader FlexLife living-benefit suite is at no extra cost versus the Premium Chronic Care Rider being optional and paid for, though rider-specific sources consistently say the Premium Chronic Care Rider costs extra [35]. Perplexity also noted it did not locate independent financial-strength evidence in its checked sources [35].

Other unresolved points: whether the $3 million maximum applies uniformly across all FlexLife issue ages or whether higher limits exist under different product tiers [38]; whether the Premium Chronic Care Rider is available in Massachusetts, where state law restricts accelerated benefit use to qualified LTC services [39]; and how the IRS per-diem limit is calculated or applied to individual buyers [40]. No independent source reviewed here verifies actual claim outcomes, consumer value, or comparative superiority versus other IUL carriers [41].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

  • What living-benefit features does National Life Group's FlexLife IUL include at no extra cost?
  • Does National Life Group's FlexLife IUL include caregiver support services, and who provides them?

FlexLife includes standard Accelerated Benefits Riders for terminal, chronic, critical illness, and critical injury at no additional cost, with the chronic illness ABR triggered by ADL impairment for 90 days and up to 100% acceleration [42]. These no-cost payouts are actuarially discounted, which is the key difference from the paid Premium Chronic Care Rider [45].

The indexed structure offers multiple crediting strategies plus a fixed interest strategy option, with a 0% floor so the policy credits no less than 0% when the index is negative, and an Accumulated Value Enhancement rider providing a 0.35% credit starting in year 11 [47]. FlexLife is available for ages 0–85 with a minimum death benefit of $50,000, and premiums and death benefit can be adjusted within limits as needs change [51].

National Life Group partnered with Homethrive to provide caregiver support services in eligible FlexLife IUL policies at no additional cost, though the services are performed by an independent third party and National Life Group will not pay or reimburse costs for them [53]. The Value Added Services Rider is available in most states but in California, Florida, and North Dakota is provided without adding the rider to the policy [56].

The lifetime limit for the Premium Chronic Care Rider is independent of the lifetime limit on other Accelerated Benefit Riders [57]. Any accelerated benefit used is deducted from both cash value and death benefit [58].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

  • How much does National Life Group's FlexLife IUL with Premium Chronic Care Rider cost per month?
  • What fees and charges apply to National Life Group's FlexLife IUL beyond the premium?
  • Can a buyer get a published price for the Premium Chronic Care Rider before applying?

No reliable public consumer premium schedule was identified for FlexLife IUL or the Premium Chronic Care Rider. Pricing is individualized and depends on age, underwriting, face amount, premium pattern, policy design, state, riders, and selected crediting options, and the chronic-care rider carries an additional charge [60]. Pricing confidence across platforms was low, with one platform reporting moderate confidence [64].

Known cost components include base IUL premiums set through individualized underwriting and policy design; an additional charge for the Premium Chronic Care Rider; and ongoing monthly policy, expense, cost-of-insurance, and applicable rider charges [60]. One platform reported a $6 monthly policy fee and premium loads of 8% in years 1–10 and 5% in year 11 and later, with moderate pricing confidence [64]. Another independent review estimated minimum monthly premiums around $10–$25 depending on product and timing [66]. These figures are platform-reported and were not independently verified.

Contract terms to note: the policy is not a deposit, is not FDIC or NCUA insured, and guarantees depend on the claims-paying ability of the issuing insurer [60]. A 10-year surrender charge schedule applies [67]. Policy loans are received income tax free, but if the policy lapses with outstanding loans there could be taxable income to the policyholder [68]. The chronic-care payout percentage is selected at issue and may be reduced but not increased after issue [60]. One source states the rider must be elected at policy issue and is available only on new FlexLife policies issued after October 24, 2025 [71].

Tax treatment of accelerated benefits is intended for favorable treatment under IRC Section 101(g), but qualification depends on factors such as life expectancy and how benefits are used, and buyers should consult a personal tax advisor [72].

Best Suited For

Questions This Section Answers

  • Who is National Life Group's FlexLife IUL with Premium Chronic Care Rider best suited for?
  • Is National Life Group a good fit for a buyer who wants permanent IUL coverage with chronic illness access?

National Life Group is best suited for a consumer who specifically wants indexed universal life, permanent coverage, cash-value potential, and an optional chronic-illness acceleration feature, and who lives in a state where the rider is approved [75]. The strongest fit is for buyers who prioritize chronic-illness access to life-insurance benefits within an IUL design and are comfortable with non-guaranteed indexed interest crediting, ongoing policy charges, and agent-mediated illustration and underwriting [75].

It also suits applicants seeking coverage issued by an insurer with a current AM Best A+ Superior rating, and buyers who value a dollar-for-dollar chronic care rider that does not discount the death benefit [77]. Buyers aged 0–85 seeking indexed universal life with a $50,000 minimum death benefit and flexible premium adjustment also fall within the product's stated parameters [79].

Probably Not Best Suited For

Questions This Section Answers

  • Who should not choose National Life Group for Indexed Universal Life Insurance With Chronic Illness or Long-Term Care Riders?
  • Is National Life Group's FlexLife IUL a poor choice for buyers in California or New York?

Buyers who need stand-alone long-term-care insurance rather than accelerated access to life-insurance proceeds should look elsewhere, because the rider is not a conventional LTC policy and does not provide a daily benefit structure [81]. Residents of California or New York seeking this specific Premium Chronic Care Rider cannot obtain it [83].

Buyers seeking simple, low-cost term insurance, guaranteed cash accumulation, or transparent public pricing before underwriting are also poor fits [81]. Consumers unable to afford additional Premium Chronic Care Rider charges who need enhanced chronic illness living benefits beyond the standard accelerated benefit rider should weigh alternatives [86]. Buyers who want to increase the chronic care rider payout percentage after policy issue cannot do so — the election is fixed at issue with reduction only [81].

When Another Option May Be Better

Questions This Section Answers

  • What is a better alternative to National Life Group for a buyer who needs guaranteed long-term care benefits?
  • When should a buyer choose a stand-alone LTC policy or a different IUL carrier instead of National Life Group?

A stand-alone long-term-care policy may be better when the buyer wants benefits designed primarily for qualified care expenses rather than acceleration of life-insurance proceeds [88]. Guaranteed universal life may be better when permanent death-benefit certainty matters more than cash-value upside, and term life plus separate long-term-care or chronic-illness coverage may be better when the buyer wants simpler pricing and clearer separation of death and care benefits [88].

A different IUL carrier may be better when the buyer's state does not approve this rider, or when another carrier offers more favorable rider definitions, lower charges, stronger guarantees, or better illustrated values [88]. One platform identified competitors with more published documentation for comparison, including John Hancock LifeCare, which is described as offering cash indemnity or reimbursement LTC benefits, 2/4/6-year benefit periods, 7702B qualification, and a 5% compound inflation rider option; Mutual of Omaha, which offers a chronic illness rider with no upfront cost and an LTC rider with recurring charges and up to $2M; and Nationwide and Brighthouse, which publish IUL long-term-care rider details [90].

Buyers who need confirmed 7702B-qualified LTC tax treatment, cash indemnity flexibility, or inflation protection options may find those features documented more clearly by competing carriers [90]. Buyers whose primary goal is maximum cash-value accumulation may also prefer carriers that specialize in that objective, since independent analysts describe FlexLife cash accumulation as average [95].

Questions to Verify Before Buying

Questions This Section Answers

  • What should a buyer confirm with National Life Group before signing a FlexLife IUL contract with the Premium Chronic Care Rider?
  • What rider definitions, charges, and state restrictions should be verified before purchase?

Before purchase, confirm which legal insurer will issue the policy and whether the Premium Chronic Care Rider is approved and available in the buyer's state [96]. Request the exact medical, functional, cognitive, certification, and waiting-period definitions that trigger the rider, and confirm whether the benefit is reimbursement-based, indemnity-style, or an acceleration of the death benefit, and how the remaining death benefit is calculated [96].

Ask for the rider charge in dollars and how it can change over time, plus the current caps, participation rates, spreads, guaranteed minimums, and illustrated assumptions for each indexed strategy [96]. Request the premium required to keep the policy in force under both guaranteed and non-guaranteed assumptions, and review how rider claims, loans, withdrawals, and accelerated benefits affect cash value, death benefit, surrender value, and taxes [96].

Confirm whether the selected payout percentage is 2% or 4% and that it cannot be increased later, and ask how the IRS per-diem limit applies to the buyer's anticipated benefit use [96]. Verify state-specific exclusions, benefit limits, or underwriting restrictions — including Massachusetts use restrictions — and request the complete policy, rider form, personalized illustration, expense pages, and in-force lapse testing before purchase [96]. Buyers should also consult a tax advisor on IRC Section 101(g) treatment and the impact of accelerated benefits on public assistance eligibility [101].

Final AI Consensus Verdict

The consensus verdict is a good fit with important qualifications. National Life Group's FlexLife IUL appears well aligned with a buyer who values permanent indexed life insurance and wants an optional chronic-illness acceleration rider. Its strongest differentiators are the stated potential to access up to the death benefit, no waiting period in the cited material, and strong current insurer financial-strength ratings [103].

The buyer should not treat it as equivalent to stand-alone long-term-care insurance, and should purchase only after comparing the rider contract, charges, state availability, benefit triggers, and guaranteed versus illustrated policy performance [103]. Five of seven platforms rated the fit good, one rated it strong, and one rated it uncertain — a spread that reflects thin independent documentation rather than a settled conclusion [107].

This review is part of the broader Indexed Universal Life Insurance With Chronic Illness or Long-Term Care Riders consensus study.

Buyers comparing carriers across the wider life insurance market should weigh whether a hybrid life-and-living-benefit structure or a dedicated care product better matches their protection goals.

How This Review Was Produced

This review was produced from a fixed research run dated 2026-09-20 in which seven AI platforms evaluated which life insurance carriers they would recommend for a consumer wanting indexed universal life insurance with chronic-illness, long-term-care, or similar living-benefit riders. Two of the seven platforms named National Life Group during the ranking stage, and all seven produced fit-research responses about the entity.

Platform fit ratings were: good (anthropic, deepseek, grok, openai, perplexity), strong (google), and uncertain (kimi). The report preserves each platform's stated findings, conflicts, and limitations without resolving them by inference. Citations are platform-reported evidence, not independently verified facts.

Methodology Limitations

Platform-reported research dates differ from the authoritative run date of 2026-09-20: anthropic, google, grok, kimi, openai, and perplexity reported 2026-09-21, while deepseek reported 2026-05-20. These are provenance metadata and do not independently prove freshness. Deepseek's response was produced with search disabled, so its claims require explicit verification before being described as current facts.

The supplied URLs were collected from platform responses and were not independently validated by the writer stage. Platform mentions count only platforms that named the entity during ranking discovery; all included platforms evaluated fit. No independent source reviewed here verifies actual claim outcomes, consumer value, or comparative superiority versus other IUL carriers. Public materials do not provide a standardized premium or rider-cost schedule, and pricing confidence was low across most platforms. Where platforms disagreed — including on documentation availability, cash-accumulation competitiveness, and whether living benefits are free or paid — the conflict is described rather than resolved.

Sources

Company-Owned Sources

Independent Sources

Other Sources

  • Additional AI research evidence108 records
    1. AI research evidence record openai:c1
    2. AI research evidence record anthropic:1-10
    3. AI research evidence record perplexity:c1
    4. AI research evidence record openai:c1
    5. AI research evidence record deepseek:nl-flexlife
    6. AI research evidence record deepseek:nl-chronic
    7. AI research evidence record openai:c1
    8. AI research evidence record anthropic:1-2
    9. AI research evidence record openai:c2
    10. AI research evidence record google:1.2.1
    11. AI research evidence record perplexity:c9
    12. AI research evidence record perplexity:c2
    13. AI research evidence record perplexity:c4
    14. AI research evidence record google:1.1.4
    15. AI research evidence record anthropic:3-2
    16. AI research evidence record openai:c1
    17. AI research evidence record anthropic:1-2
    18. AI research evidence record anthropic:1-7
    19. AI research evidence record grok:0
    20. AI research evidence record perplexity:c1
    21. AI research evidence record google:1.1.1
    22. AI research evidence record anthropic:1-10
    23. AI research evidence record anthropic:29-11
    24. AI research evidence record anthropic:1-8
    25. AI research evidence record perplexity:c2
    26. AI research evidence record openai:c3
    27. AI research evidence record openai:c4
    28. AI research evidence record anthropic:20-2
    29. AI research evidence record anthropic:27-1
    30. AI research evidence record grok:15
    31. AI research evidence record anthropic:11-12
    32. AI research evidence record kimi:merrillconnect_unclear
    33. AI research evidence record google:1.1.1
    34. AI research evidence record google:1.2.9
    35. AI research evidence record perplexity:c1
    36. AI research evidence record perplexity:c2
    37. AI research evidence record perplexity:c12
    38. AI research evidence record anthropic:1-2
    39. AI research evidence record anthropic:1-10
    40. AI research evidence record anthropic:1-7
    41. AI research evidence record openai:c1
    42. AI research evidence record anthropic:7-1
    43. AI research evidence record anthropic:18-1
    44. AI research evidence record anthropic:18-2
    45. AI research evidence record google:1.1.4
    46. AI research evidence record perplexity:c2
    47. AI research evidence record anthropic:33-6
    48. AI research evidence record anthropic:33-7
    49. AI research evidence record anthropic:35-1
    50. AI research evidence record anthropic:35-3
    51. AI research evidence record anthropic:8-3
    52. AI research evidence record anthropic:34-1
    53. AI research evidence record google:1.2.3
    54. AI research evidence record anthropic:1-11
    55. AI research evidence record anthropic:1-12
    56. AI research evidence record anthropic:1-10
    57. AI research evidence record anthropic:1-9
    58. AI research evidence record anthropic:13-4
    59. AI research evidence record anthropic:13-6
    60. AI research evidence record openai:c1
    61. AI research evidence record anthropic:1-2
    62. AI research evidence record deepseek:nl-chronic
    63. AI research evidence record perplexity:c9
    64. AI research evidence record grok:0
    65. AI research evidence record anthropic:11-12
    66. AI research evidence record anthropic:30-1
    67. AI research evidence record google:1.1.6
    68. AI research evidence record anthropic:28-2
    69. AI research evidence record anthropic:28-3
    70. AI research evidence record anthropic:1-8
    71. AI research evidence record perplexity:c2
    72. AI research evidence record anthropic:14-5
    73. AI research evidence record anthropic:14-8
    74. AI research evidence record anthropic:14-4
    75. AI research evidence record openai:c1
    76. AI research evidence record anthropic:1-2
    77. AI research evidence record openai:c3
    78. AI research evidence record perplexity:c2
    79. AI research evidence record anthropic:8-3
    80. AI research evidence record anthropic:34-1
    81. AI research evidence record openai:c1
    82. AI research evidence record anthropic:3-2
    83. AI research evidence record anthropic:1-10
    84. AI research evidence record grok:0
    85. AI research evidence record perplexity:c1
    86. AI research evidence record anthropic:1-2
    87. AI research evidence record anthropic:1-8
    88. AI research evidence record openai:c1
    89. AI research evidence record deepseek:nl-chronic
    90. AI research evidence record kimi:jhlifecare_guide
    91. AI research evidence record kimi:jhlifecare_consumer
    92. AI research evidence record kimi:mutualofomaha_rider
    93. AI research evidence record kimi:nationwide_iul
    94. AI research evidence record kimi:brighthouse_smartcare
    95. AI research evidence record google:1.2.9
    96. AI research evidence record openai:c1
    97. AI research evidence record anthropic:1-10
    98. AI research evidence record perplexity:c2
    99. AI research evidence record anthropic:28-3
    100. AI research evidence record anthropic:1-7
    101. AI research evidence record anthropic:14-4
    102. AI research evidence record anthropic:14-8
    103. AI research evidence record openai:c1
    104. AI research evidence record openai:c3
    105. AI research evidence record openai:c4
    106. AI research evidence record anthropic:3-2
    107. AI research evidence record kimi:merrillconnect_unclear
    108. AI research evidence record google:1.1.1

Verify this research

Check when the research was run, which platforms were included, and what supports the findings.

Study date
September 20, 2026
Platforms analyzed
7
Source records
45
Ranking mentions
2 of 7
Platform share
29%
Final consensus rank
#6

Behind the findings

Platforms in this study

  • ChatGPT
  • Claude
  • DeepSeek
  • Grok
  • Perplexity
  • Kimi
  • Gemini

Source records

19 independent · 19 company-owned · 7 unclear

Evidence support

22 direct · 8 partial

Keep in mind

Use the run research_date as the study date. Platform-reported dates are provenance metadata and do not independently prove freshness.

Technical verification details

Use this SHA-256 fingerprint to identify the source snapshot associated with this study.

c23287a3964b2705497d1aeb486fdb171d8c68dc26709d3024064313a27da2fe